Characterization of HIV-1 neutralization escape mutants

McKeating, Jane A.; Gow, John; Goudsmit, Jaap; Pearl, Laurence H.; Mulder, Carel; Weiss, Robin A.

doi:10.1097/00002030-198912000-00001

Cited by 203 publications

(124 citation statements)

References 0 publications

Supporting

Mentioning

122

Contrasting

Order By: Relevance

“…However, this hypothesis is far too simplistic. Several longitudinal studies [32,33] have shown the occurrence of viral neutralization escape in the presence of conserved V3 linear sequence. In addition, it has recently been shown that neutralization of divergent HIV isolates might be due to antibodies recognizing other regions than V3, which may be linear or conformational [34,35].…”

Section: Discussionmentioning

confidence: 99%

Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children

Broliden

Sievers

Tovo

et al. 1993

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYThe prognostic and protective role of antibodies mediating cellular cytotoxicity (ADCC) and neutralization was evaluated in sera of HIV-1-infected mothers and their consecutively followed children. The presence and titres of ADCC mediating and/or neutralizing antibodies in maternal sera did not predict HIV-1 infection in their respective children. No significant diflFerence in the sera from the children was seen when comparing the presence of neutralizing antibodies between the uninfected and infected children. Stratification of the infected group according to clinical status revealed differences. Only one of 24 AIDS patients had a high neutralizing titre against IIIB. Four patients had a very low titre and the remaining had no detectable neutralizing antibodies at all. In contrast, 10/17 infected non-AIDS children had neutralizing antibodies. Similarly, no significant difference was seen when comparing the presence of ADCC-mediating antibodies between the uninfected and the infected group of children. However, a significantly higher frequency of ADCC was seen in the seropositive non-AIDS children compared with the AIDS children. This study clearly shows that the presence of antibodies mediating ADCC and neutralization in infected children, 0-2 years old, is associated with a better clinical status and delayed disease progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children

Broliden

Sievers

Tovo

et al. 1993

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…For example, the high mutation rate of certain viruses enables them to escape neutralization [49]. This problem may be overcome by using mixtures of mAbs that target various areas of bio-threat agents.…”

Section: Cocktail Of Mabsmentioning

confidence: 99%

Opportunities and Challenges of Therapeutic Monoclonal Antibodies as Medical Countermeasures for Biodefense

Hu¹,

Nagata²

2016

J Bioterror Biodef

View full text Add to dashboard Cite

Antibodies, naturally produced in the body as part of the immune response to infectious agents, can also be introduced artificially to treat infectious diseases. Advances in biotechnology in the last decades have made human or humanized monoclonal antibodies (mAbs) as therapeutics possible. These therapeutic mAbs currently enjoy unprecedented success and recognition of their potential. Unlike vaccines, therapeutic mAbs can confer instant and consistent protection against bio-threat agents when administered regardless of the recipient's immune status. Therapeutic mAbs can be administered in higher levels than those elicited by vaccines, and thus provide a higher level of protection or treatment that is necessary in a biological attack where people are exposed to a higher exposure of agent concentration than that found in nature. Furthermore, therapeutic mAbs have substantial advantages over antimicrobial drugs, such as high specificity, low systemic toxicity, relatively long half-life, and no concerns over disrupting the body's microbiome. Therapeutic mAbs can be used for both pre-and post-exposure protection; therefore, they have great value as effective medical countermeasures (MedCMs) against bio-threat agents. However, there are still some challenges to be overcome before therapeutic mAbs become ideal MedCMs against bio-threat agents. In this review, both opportunities and challenges in development of therapeutic mAbs are discussed.

show abstract

“…Nevertheless, selection of HIV-1 escape mutants by neutralizing MoAbs should be considered, since this phenomenon was described in vitro (Reitz et al, 1988;McKeating et al, 1989) and in vivo (Nara et at., 1990).…”

Section: Discusstonmentioning

confidence: 99%

Characterization and large production of human monoclonal antibodies against the HIV-1 envelope

Boyer

Broly

Souche

et al. 1991

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYPeripheral blood lymphocytes from a volunteer immunized with a reeombinant vaccinia virus VSC-25 expressing the gpl60 env protein of HTLV-IIIB strain and from an asymptomatic HIV-infected individual were immortalized by Epstein-Barr (EBV). Clones which secrete human monoclonal antibodies from the two individuals (DZ, IgGl, I and C3!, IgGl, K) were obtained and were stable for more than 2 years. The two monoclonals were directed against the gp 160 env protein of HI V, DZ directed against the gp41 and C31 directed against the gpl20. C31 was group-specific, whereas DZ was directed against the HTLV-IIIB and HTLV-RF strains. The epitope recognized by DZ was mapped to the carboxy terminus of the gp41, by expression of HIV DNA fragments in a yeast system and peptide analysis. The C31 epitope was not expressed by the yeast library and not present among the peptides which were tested. Monoclonal antibodies had no inhibitory effect in an HIV-induced cell fusion assay, but DZ showed a weak neutralizing activity against the HTLV-IIIB strain. Cloned EBV-transformed cell lines were fused to a murine myeloma, which allowed the heteromyeloma to be cultivated in serum-free medium. The monoclonal antibodies were produced in large quantity in a hollow-fibre reactor at defined culture conditions and purification procedures.

show abstract

Characterization of HIV-1 neutralization escape mutants

Cited by 203 publications

References 0 publications

Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children

Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children

Opportunities and Challenges of Therapeutic Monoclonal Antibodies as Medical Countermeasures for Biodefense

Characterization and large production of human monoclonal antibodies against the HIV-1 envelope

Contact Info

Product

Resources

About